Log in

Clovis Oncology Price Target & Analyst Ratings (NASDAQ:CLVS)

$6.31
-0.24 (-3.66 %)
(As of 11/15/2019 04:53 AM ET)
Today's Range
$5.97
Now: $6.31
$7.00
50-Day Range
$3.00
MA: $3.86
$6.56
52-Week Range
$2.93
Now: $6.31
$32.05
Volume15.84 million shs
Average Volume3.03 million shs
Market Capitalization$345.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Analyst Ratings

Clovis Oncology (NASDAQ:CLVS) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Their average twelve-month price target is $20.73, suggesting that the stock has a possible upside of 228.48%. The high price target for CLVS is $36.00 and the low price target for CLVS is $4.00. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.432.402.502.73
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.73$22.27$25.50$35.63
Price Target Upside: 228.48% upside449.94% upside349.74% upside89.80% upside

Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/31/2019Piper Jaffray CompaniesLower Price TargetNeutral$11.00 ➝ $4.00High
9/30/2019HC WainwrightSet Price TargetBuy$36.00Medium
9/30/2019JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/27/2019Bank of AmericaSet Price TargetHold$7.00Medium
9/24/2019Svb LeerinkDowngradeOutperform ➝ Market Perform$22.00 ➝ $10.00High
9/24/2019Leerink SwannDowngradeOutperform ➝ Market Perform$10.00High
8/2/2019G.ResearchReiterated RatingBuyHigh
8/2/2019BarclaysSet Price TargetBuy$36.00Low
8/2/2019Royal Bank of CanadaSet Price TargetBuy$26.00Low
8/2/2019GabelliReiterated RatingBuyHigh
8/1/2019GuggenheimDowngradeBuy ➝ NeutralHigh
5/29/2019Goldman Sachs GroupDowngradeNeutral ➝ Sell$17.00 ➝ $15.00Low
5/15/2019Credit Suisse GroupReiterated RatingBuy$29.00High
4/15/2019SunTrust BanksLower Price TargetBuy$28.00Medium
10/30/2018OppenheimerReiterated RatingHoldHigh
2/27/2018Stifel NicolausLower Price TargetBuy ➝ Buy$125.00 ➝ $110.00Medium
2/22/2018Evercore ISIUpgradeIn-Line ➝ Outperform$72.00High
(Data available from 11/15/2017 forward)
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel